Pseudo-hypopyon as the presenting feature of recurrent B-cell lymphoma.
OBJECTIVE
To report a case of a pseudo-hypopyon as the presentation for recurrent B-cell lymphoma.


METHODS
Case report.


METHODS
Case report with anterior segment photograph.


RESULTS
A 74-year-old man with past medical history of peripheral B-cell lymphoma developed a hypopyon 3 months after R-CHOP chemotherapy and prophylactic intrathecal chemotherapy. Anterior chamber aspirate was consistent with B-cell lymphoma.


CONCLUSIONS
Pseudo-hypopyon as a manifestation of recurrent B-cell lymphoma is a rare clinical presentation of an intraocular malignancy. A high index of suspicion along with intraocular fluid analysis are essential to establish the diagnosis.
Papaliodis
George Nick
GN
Massachusetts Eye and Ear Infirmary, Boston, Massachusetts 02114, USA. gpapaliodis@partners.org
Montezuma
Sandra R
SR
D000368:Aged; D000867:Anterior Chamber / Q000473:pathology; D000869:Anterior Eye Segment / Q000473:pathology; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001082:Aqueous Humor / Q000166:cytology; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005128:Eye Diseases / Q000209:etiology* / Q000473:pathology; D006801:Humans; D007278:Injections, Spinal; D016393:Lymphoma, B-Cell / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009367:Neoplasm Staging; D011239:Prednisolone / Q000627:therapeutic use; D000069283:Rituximab; D013492:Suppuration; D014750:Vincristine / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone